Universität zu Köln

van Asten, Freekje ORCID: 0000-0002-8141-4234, Rovers, Maroeska M., Lechanteur, Yara T. E., Smailhodzic, Dzenita, Muether, Philipp S., Chen, John, den Hollander, Anneke I., Fauser, Sascha, Hoyng, Carel B., van der Wilt, Gert Jan ORCID: 0000-0002-5856-762X and Klevering, B. Jeroen (2014). Predicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration. Ophthalmic Epidemiol., 21 (6). S. 347 - 356. PHILADELPHIA: TAYLOR & FRANCIS INC. ISSN 1744-5086

Full text not available from this repository.

Abstract

Purpose: To validate known and determine new predictors of non-response to ranibizumab in patients with neovascular age-related macular degeneration (AMD) and to incorporate these factors into a prediction rule. Methods: This multicenter, observational cohort study included 391 patients treated with ranibizumab for neovascular AMD. We performed genetic analysis for single nucleotide polymorphisms in AMD-associated genes and collected questionnaires regarding environmental factors and disease history. The primary outcome was non-response to treatment, defined as a loss of visual acuity >= 30% of letters. Results: Of the 391 patients, 47 were classified as non-responsive. Independent predictors for non-response were age, baseline visual acuity, diabetes mellitus and accumulation of risk alleles in the CFH, ARMS2 and VEGF-A genes. The area under the receiver operating characteristic curve was 0.77 (95% confidence interval 0.70-0.84). We derived a clinical prediction rule, with possible total risk scores ranging from 0-19 points. The absolute risk of non-response varied from 3-52% between risk score groups. Conclusion: This is an important step towards a clinical prediction rule that can aid clinicians in identifying AMD patients with increased likelihood of non-response, and consequently contribute to making shared treatment decisions.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code van Asten, Freekje UNSPECIFIED orcid.org/0000-0002-8141-4234 UNSPECIFIED Rovers, Maroeska M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lechanteur, Yara T. E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Smailhodzic, Dzenita UNSPECIFIED UNSPECIFIED UNSPECIFIED Muether, Philipp S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Chen, John UNSPECIFIED UNSPECIFIED UNSPECIFIED den Hollander, Anneke I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fauser, Sascha UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoyng, Carel B. UNSPECIFIED UNSPECIFIED UNSPECIFIED van der Wilt, Gert Jan UNSPECIFIED orcid.org/0000-0002-5856-762X UNSPECIFIED Klevering, B. Jeroen UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-422784
DOI:	10.3109/09286586.2014.949010
Journal or Publication Title:	Ophthalmic Epidemiol.
Volume:	21
Number:	6
Page Range:	S. 347 - 356
Date:	2014
Publisher:	TAYLOR & FRANCIS INC
Place of Publication:	PHILADELPHIA
ISSN:	1744-5086
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language COMPLEMENT FACTOR-H; INTRAVITREAL RANIBIZUMAB; SUBGROUP ANALYSIS; POOLED FINDINGS; RISK-FACTORS; BEVACIZUMAB; ASSOCIATION; THERAPY; VERTEPORFIN; MACULOPATHY Multiple languages Ophthalmology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/42278